A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
To determine the long-term (approximately 2 years) nephroprotective potential of treatment
with sparsentan as compared to an angiotensin receptor blocker in patients with
immunoglobulin A nephropathy (IgAN).